| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b864b811ae7d2a1841bbf1c1d17da9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c75ffaae496cba1cfc490f3921f98fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f945abf85301393f532229dfe1567eec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09f6b7dea9b4703435eb18bfeafe6932
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11bdbadfe81e92dead4de89084e384c4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate |
2008-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_192585221bc94fdd39f266da8739b336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75f61a03a172ac79f85cac845a9dab0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e343c09e35d173bc01993878d77bb56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8465c77a6c02ef42702b9f1346e948f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a557733afa347504e261abd782b011 |
| publicationDate |
2009-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009041666-A1 |
| titleOfInvention |
Ophthalmic formulations of Amyloid-beta contrast agent and methods of use thereof |
| abstract |
The invention provides ophthalmic formulations of Amyloid-β contrast agents. Also provided are methods of using such formulations in the diagnosis of Alzheimer's Disease or a predisposition thereto as well as methods for the prognosis of Alzheimer's Disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10512699-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9839699-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022142929-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011286932-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9149184-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2420179-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013208245-A1 |
| priorityDate |
2007-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |